JGC
JNCE

J. Goldman & Co’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

J. Goldman & Co’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-24,120
Closed -$539K – 480
2018
Q1 		$539K Sell
24,120
-25,880
-52% -$574K 0.02% 280
2017
Q4 		$638K Buy
+50,000
New +$735K 0.03% 255

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

J. Goldman & Co's JNCE Position: Q2 2018 in Review

J. Goldman & Co sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2018, closing a stake of 24,120 shares — an estimated $539K sold.

J. Goldman & Co first reported a position in JNCE in Q4 2017 and held it in 2 quarters. The position peaked at $638K in Q4 2017. 83 funds tracked by Wall St. Rank hold JNCE as of Q2 2018.

  • J. Goldman & Co reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • J. Goldman & Co sold 24,120 Jounce Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $539K.
  • J. Goldman & Co first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • J. Goldman & Co's Jounce Therapeutics, Inc. Common Stock position peaked at $638K in Q4 2017.
  • 83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2018.

Based on J. Goldman & Co's 13F filing for Q2 2018, filed 14 Aug 2018.